112921-00-3

Basic information

• Product Name: ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl sulfamate
• Synonyms: ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl sulfamate
• CAS NO: 112921-00-3
• Molecular Weight: 386.389
• Mol File: 112921-00-3.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl sulfamate(CAS DataBase Reference)
• NIST Chemistry Reference: ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl sulfamate(112921-00-3)
• EPA Substance Registry System: ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl sulfamate(112921-00-3)

Safety Data

• Hazardous Substances Data: 112921-00-3(Hazardous Substances Data)

Usage

General Description

The chemical compound with the IUPAC name ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl sulfamate is a sulfamate derivative with a purine base. It has a molecular formula of C11H16N6O6S and a molecular weight of 364.34 g/mol. ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl sulfamate is a potential drug candidate due to its ability to inhibit carbonic anhydrase enzymes, which are involved in various physiological processes, including regulating acid-base balance. Additionally, it has shown promise in the treatment of certain neurological and psychiatric conditions. Further research and development of this compound may lead to new therapeutic applications in medicine.

Upstream product

• 24639-06-3 ((3aR,4R,6R,6aR)-6-(6-amino-2-chloro-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 
• 146-77-0 2-Chloroadenosine 
• 362-75-4 2',3'-isopropylidene adenosine 
• 58-61-7 adenosine 

Downstream Products

• 873556-43-5 5'-O-(N-(benzoyl)sulfamoyl)-2',3'-O-isopropylideneadenosine 
• 873556-40-2 5'-O-(N-(2-carbobenzyloxyaminobenzoyl)sulfamoyl)-2',3'-O-isopropylideneadenosine 
• 939794-52-2 5'-O-[N-(2-chlorobenzoyl)sulfamoyl]-2',3'-O-isopropylideneadenosine 
• 939794-75-9 5'-O-[N-(5-chloro-2-hydroxybenzoyl)sulfamoyl]2',3'-O-isopropylideneadenosine 
• 939794-70-4 5'-O-[N-(3-chloro-2-hydroxybenzoyl)sulfamoyl]-2',3'-O-isopropylideneadenosine 
• 960500-67-8 C₂₀H₁₇F₄N₉O₇S 
• 939794-65-7 C₃₄H₃₄N₆O₉S 
• 939794-78-2 C₂₀H₂₁FN₆O₈S 
• 960500-65-6 5'-O-{N-[N-(t-butyloxycarbonyl)-L-phenylalanyl]sulfamoyl}-2',3'-O-isopropylideneadenosine 
• 879093-39-7 salicylic 2′,3′-O-isopropylideneadenosine monosulfonamide 

Relevant articles and documents

An orthogonal seryl-tRNA synthetase/tRNA pair for noncanonical amino acid mutagenesis in Escherichia coli

We report the development of the orthogonal amber-suppressor pair Archaeoglobus fulgidus seryl-tRNA (Af-tRNASer)/Methanosarcina mazei seryl-tRNA synthetase (MmSerRS) in Escherichia coli. Furthermore, the crystal structure of MmSerRS was solved at 1.45 ? resolution, which should enable structure-guided engineering of its active site to genetically encode small, polar noncanonical amino acids (ncAAs).

A FACILE SYNTHESYS OF ASCAMYCIN AND RELATED ANALOGUES

The nucleoside antibiotic ascamycin (2-chloro-5'-O-(N-(L-alanyl)sulfamoyl)adenosine (1)) has been synthesized by an improved procedure involving the direct condensation of 2-chloro-2',3'-O-isopropylidene-5'-O-sulfamoyladenosine (3) with Boc-L-Ala-OSu in DMF and the presence of DBU, followed by removal of the protecting groups.A similar condensation of 3 with Boc-D-Ala-Osu and Boc-Gly-Osu, and subsequent deprotection, yielded the D-Ala and Gly analogues of 1, namely 2-chloro-5'-O-(N-(D-alanyl)sulfamoyl) and 2-chloro-5'-O-(N-(glycyl)sulfamoyl)adenosine (D-ascamycin (14) and (18)).Similar reactions of 2',3'-O-isopropylidene-5'-O-sulfamoyladenosine, (6) with the tree amino acid derivatives above mentioned provided the corresponding adenosine analogues 12,16, and 20.Several studies directed to demonstrate that the previous protection of the 6-NH2 group of the adenosine derivatives 3 and 6 is not necessary for the selective aminoacylation of the SO2NH2 group are also reported.

Synthesis and aminoacyl-tRNA synthetase inhibitory activity of prolyl adenylate analogs

Two nonhydrolyzable prolyl adenylate analogs, 5'-O-[N-(L-prolyl)-sulfamoyl]adenosine (L-PSA) and 5'-O-[N-(D-prolyl)-sulfamoyl]adenosine (D-PSA), were prepared in three steps from 2',3'-di-O-isopropylideneadenosine. Both of these compounds inhibited the in vitro activity of Escherichia coli and human prolyl-tRNA synthetase (ProRS). The human enzyme used in this study was derived from the carboxy-terminal domain of the multifunctional human EPRS gene. The K(i)(ATP) values for L-PSA, determined using the ATP-PP(i) exchange assay, are very similar for both synthetases (~1-2 nM). The K(i)(Pro) values, on the other hand, vary approximately seven-fold between the two synthetases (0.6 nM for human and 4.3 nM for E. coli). The K(i) values measured for the D-PSA analog are much higher (51-470 nM) for all cases examined; however, the same species-specific differences are observed with respect to K(i)(Pro). These results indicate possible structural differences in or near the active sites of the two enzymes that may be exploited in the future design of compounds that function as species-specific synthetase inhibitors in vivo.

Integrated Target-Based and Phenotypic Screening Approaches for the Identification of Anti-Tubercular Agents That Bind to the Mycobacterial Adenylating Enzyme MbtA

Iron is essential for the pathogenicity and virulence of Mycobacterium tuberculosis, which synthesises salicyl-capped siderophores (mycobactins) to acquire this element from the host. MbtA is the adenylating enzyme that catalyses the initial reaction of mycobactin biosynthesis and is solely expressed by mycobacteria. A 3200-member library comprised of lead-like, structurally diverse compounds was screened against M. tuberculosis for whole-cell inhibitory activity. A set of 846 compounds that inhibited the tubercle bacilli growth were then tested for their ability to bind to MbtA using a fluorescence-based thermal shift assay and NMR-based Water-LOGSY and saturation transfer difference (STD) experiments. We identified an attractive hit molecule, 5-hydroxyindol-3-ethylamino-(2-nitro-4-trifluoromethyl)benzene (5), that bound with high affinity to MbtA and produced a MIC90 value of 13 μm. The ligand was docked into the MbtA crystal structure and displayed an excellent fit within the MbtA active pocket, adopting a binding mode different from that of the established MbtA inhibitor Sal-AMS.